Table 5.
Multivariable analysis of outcomes among patients with multiple myeloma receiving transplants from allogeneic donors following non-myeloablative conditioning
| Variable | Relapsed auto | Risk group a | B2M>4.0 | Tandem auto | Female donor | No. before regimens | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95%CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Survival | 2.51 (1.1–5.8) | 0.03 | NS | 2.56 (1.2–5.6) | 0.02 | NS | NS | NS | ||||
| PFS | 2.89 (1.4–6.1) | 0.005 | 2.45 (1.5–3.9) | 0.0002 | 2.39 (1.1–5.1) | 0.03 | NS | NS | ||||
| TRM | NS | NS | NS | 0.16 (0.0–0.6) | 0.004 | NS | ||||||
| Rel/Prog | 5.42 (2.2–14) | 0.0003 | 3.18 (1.8–5.6) | <0.0001 | 2.92 (1.2–7.1) | 0.02 | NS | 0.50 (0.3–0.9) | 0.01 | 0.77 (0.6–1.0) | 0.04 | |
aChemotherapy-responsive or -resistant disease.